Search

Your search keyword '"Carlino F"' showing total 167 results
Start Over Author "Carlino F"
167 results on '"Carlino F"'

10. Metachronous Gastrointestinal Stromal Tumors (Gists) or relapse of the primary tumor ? A challenging case of multiple Gists in an elderly patient

Author

Guerrera LP, Diana A, Franzese E, Carlino F, Perrone A, Centonze S, Ronchi A, Ruggiero R, Parisi S, Lucido FS, Alfano R, Ciardiello F, Orditura M, Docimo L, Guerrera, Lp, Diana, A, Franzese, E, Carlino, F, Perrone, A, Centonze, S, Ronchi, A, Ruggiero, R, Parisi, S, Lucido, F, Alfano, R, Ciardiello, F, Orditura, M, and Docimo, L

Subjects
KIT mutations, Sporadic, Multiple primary, digestive system diseases, GIST
Abstract

Background: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal cancers of the gastrointestinal tract PDGFRA genes. Sporadic Multiple Primary GISTs (MPGs) are a rare entity that could occur in adult patients characterized by multiple synchronous lesions generally located in the same organ and even more rarely by metachronous neoplasms. The differential diagnosis among MPGs and disseminated disease or recurrent primary GIST is critical as it affects clinical management. Case report: Here, we present a case of an 86-year-old female who underwent emergency surgery in June 2016 for a giant GIST of the stomach occupying most of the left side of the abdomen. After two years, during adjuvant imatinib 400 mg daily, emergency sigmoid resection was performed due to subacute obstruction and a colonic GIST carrying the same KIT mutation (deletion 557-558 at exon 11) of the previous gastric neoplasm was detected. In this case, we hypothesized the primary nature of the two tumors despite being metachronous and occurring in different organs. However, the same mutational pattern suggested a clonal relationship between the two neoplasms. The onset of a third duodenal lesion, that could corroborate the assumption of the primary metachronous nature of the disease, still remains an unsolved question since its malignancy was not confirmed. Conclusion: Differentiating among metachronous multiple primary GISTs or relapse on imatinib is relevant for staging and choosing the most proper therapeutic approach. Further investigations are surely needed in order to asses a diagnostic tool that may help clinicians to distinguish this rare entity (both synchronous or metachronous) from recurrences. In this scenario, molecular analysis may add essential data to discriminate sporadic MPGs and recurrent or metastatic GISTs.

Published
2020

13. 3O Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer

Author

Diana, A., primary, Della Corte, C.M., additional, Carlino, F., additional, Ciaramella, V., additional, Franzese, E., additional, Centonze, S., additional, Trovato, C., additional, Vassallo, I., additional, Iovino, F., additional, Procaccini, E., additional, Ciardiello, F., additional, Morgillo, F., additional, and Orditura, M., additional

Published
2020
Full Text
View/download PDF

14. 183P Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor negative (HER2-) early breast cancer

Author

Diana, A., primary, Iovino, F., additional, Carlino, F., additional, Perrone, A., additional, Trovato, C., additional, Vassallo, I., additional, Antoniol, G., additional, Caraglia, M., additional, Franco, R., additional, Ciardiello, F., additional, and Orditura, M., additional

Published
2020
Full Text
View/download PDF

32. [Treatment of chronic hepatitis C with lymphoblastic interferon. Long-term follow-up]

Author

PASSARIELLO, Nicola, Sepe J, Peluso A, Carlino F, Guglielmelli V, Esposito P, ROSSIELLO, Raffaele, d'Onofrio F, Sgambato S., Passariello, Nicola, Sepe, J, Peluso, A, Carlino, F, Guglielmelli, V, Esposito, P, Rossiello, Raffaele, D'Onofrio, F, and Sgambato, S.

Subjects
Adult, Male, Time Factors, Interferon-alpha, Alanine Transaminase, Middle Aged, Antiviral Agents, Hepatitis C, Double-Blind Method, Liver, Chronic Disease, Humans, Female, Follow-Up Studies
Abstract

A randomized controlled trial was set up to assess the effect of two different therapy regimens with lymphoblastoid interferon on the treatment and follow-up of patients with chronic C hepatitis.Eighty-five patients with chronic hepatitis C were randomized into two treatment groups (n = 30 respectively) and one control group (no treatment: n = 25). In one treatment group patients received three million units of alpha-lymphoblastoid interferon. The other received six million units.A rapid decline in both alanine aminotransferase and aspartataminotransferase levels was seen in most treated patients (a complete response in 51% from group A and 55% from group B; partial response 29% from group A, 25% from group B). In five partial responders and six complete responders from group A and in seven partial responders and six complete responders in group B serum aminotransferase levels returned to baseline values in the follow-up. No change in serum bilirubin, albumin, IgG and prothrombin time during interferon treatment were seen. The histologic staging remained unchanged throughout the entire study.alpha-interferon treatment improves the clinical picture, biochemical parameters and histologic pattern in a large percentage of patients with hepatitis C. Long-term remission was seen in only 37% of treated patients. Using six million units of alpha-interferon has not proven to be significantly better than three million units. Protracted treatment for nine months seems to increase the percentage of patients in biochemical and histologic remission.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results